The global cell freezing media market was valued at USD 1.17 billion in 2024 and is projected to reach USD 2.37 billion by 2033, registering a CAGR of 8.58% from 2025 to 2033. This growth is driven by the increasing adoption of commercial cell freezing media as a reliable alternative to in-house preparations, along with the advantages of ready-to-use cryopreservation formulations over conventional freezing techniques. Additionally, rising demand for effective freezing media across a broad spectrum of end-users and the introduction of innovative products by key market players are expected to further support market expansion.
A significant contributor to market growth is the rapid expansion of biobanking activities worldwide. Biobanks play a crucial role in storing and preserving biological specimens—including human cells, tissues, and biofluids—for biomedical research, diagnostics, and therapeutic development. As genomic research, disease modeling, and biomarker discovery advance, there is an increased need for high-quality, viable samples that require robust cryopreservation solutions to maintain long-term stability and functionality. The growing emphasis on personalized and precision medicine further strengthens this demand, as researchers require diverse, well-preserved samples to analyze genetic variations and develop tailored therapies. To meet these evolving needs, biobanks are increasingly adopting serum-free, xeno-free, and regulatory-compliant freezing media, particularly for samples intended for clinical use.
Key Market Trends & Insights
- North America accounted for the largest share of the global market at 38.19% in 2024.
- The U.S. cell freezing media industry is expected to experience significant growth throughout the forecast period.
- By product, the DMSO segment dominated with a 70.87% share in 2024.
- By application, the stem cells segment held the largest share at 28.99% in 2024.
- By end use, pharmaceutical and biotechnology companies led the market with a 40.20% share in 2024.
Download a free sample PDF of the Cell Freezing Media Market Intelligence Study by Grand View Research.
Market Size & Forecast
- 2024 Market Size: USD 1.17 Billion
- 2033 Projected Market Size: USD 2.37 Billion
- CAGR (2025–2033): 8.58%
- Largest Market (2024): North America
- Fastest-Growing Region: Asia Pacific
Competitive Landscape
The market is dominated by established players with extensive product portfolios, strong technological capabilities, and global distribution networks. Leading companies such as Merck KGaA, Sartorius AG, Thermo Fisher Scientific Inc., and BioLife Solutions, Inc. leverage their expertise in the life sciences sector to develop high-quality, GMP-compliant, serum-free, and xeno-free cryopreservation media tailored for both research and clinical use.
Other key players—including HiMedia Laboratories, Bio-Techne, PromoCell GmbH, Capricorn Scientific, Vitrolife AB, AMSBIO, and ZENOGEN PHARMA CO., LTD.—are strengthening their market presence by offering specialized formulations designed for sensitive cell types such as stem cells, immune cells, and reproductive cells. Many of these companies are also integrating their products with automated freezing systems to enhance scalability, process consistency, and post-thaw cell viability.
Prominent Companies
- Merck KGaA
- Sartorius AG
- HiMedia Laboratories
- Thermo Fisher Scientific Inc.
- BioLife Solutions, Inc.
- Bio-Techne
- PromoCell GmbH
- Capricorn Scientific
- Vitrolife AB
- AMSBIO
- ZENOGEN PHARMA CO., LTD.
Explore Horizon Databook – the world’s most comprehensive market intelligence platform by Grand View Research.
Conclusion
The global cell freezing media market is positioned for steady expansion through 2033, supported by the growing adoption of ready-to-use cryopreservation solutions and the rising shift away from traditional in-house formulations. Increasing biobanking activities, the surge in precision medicine initiatives, and the need for high-quality, viable biological samples are further strengthening market demand. As end-users prioritize serum-free, xeno-free, and regulatory-compliant media, manufacturers are innovating to provide more specialized and application-specific formulations. With strong participation from leading life science companies and the continued integration of automated freezing technologies, the market is expected to maintain a robust growth trajectory, playing a crucial role in advancing research, therapeutic development, and personalized medicine worldwide.
No comments:
Post a Comment